Physiological Effect: Decreased Platelet Production

Drugs with Physiological Effect: Decreased Platelet Production

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	209151-001	Jun 30, 2017	AB	RX	No	No
Torrent	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	209151-002	Jun 30, 2017	AB	RX	No	No
Chartwell Rx	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076683-001	Apr 18, 2005		DISCN	No	No
Chartwell Rx	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076683-002	Apr 18, 2005		DISCN	No	No
Novitium Pharma	ANAGRELIDE HYDROCHLORIDE	anagrelide hydrochloride	CAPSULE;ORAL	076811-001	Apr 18, 2005	AB	RX	No	No

Last updated: July 7, 2026

Market dynamics and patent landscape for drugs that decrease platelet production

Drugs that reduce platelet counts most often act by interrupting megakaryopoiesis (the platelet-formation pathway) or by targeting platelet survival. The patent landscape splits into two commercial lanes: (1) thrombopoietin-pathway inhibitors used for thrombocytosis and (2) cytotoxic or immunologic regimens that secondarily cause thrombocytopenia. Exclusivity and entry risk depend on whether the product is a licensed, indication-specific agent or a broadly off-label consequence of a regimen.

Because the request is scoped to “drugs with the physiological effect: decreased platelet production” without naming specific active ingredients, the most decision-useful approach is to map the strongest, most direct platelet-lowering category and then characterize how the patent estate and market dynamics look across adjacent mechanism classes.

How do thrombopoietin (TPO) pathway inhibitors work and what patents protect them?

TPO-pathway inhibition is the cleanest regulatory and commercial match to “decreased platelet production.” In practice, the most prominent product family is the JAK2 inhibitor class used in myeloproliferative neoplasms (MPNs) and direct TPO-pathway suppressors (including anti-TPO strategies when they are licensed).

Featured mechanism cluster

• Reduce thrombocytosis in MPNs (most commonly essential thrombocythemia, polycythemia vera-related thrombocytosis, and similar settings).
• Downshift megakaryocyte signaling through JAK-STAT modulation or direct pathway inhibition.
• Drive platelet count response while maintaining tolerability profile.

Which active ingredients dominate the “platelet-lowering” patent space in practice?

Within licensed platelet-lowering therapy, the “most patent-dense” estates usually attach to:

• JAK inhibitors for MPN-associated thrombocytosis and myelofibrosis-related platelet dynamics
• Cytoreductive agents whose platelets drop as a consequence of cell-cycle inhibition
• Immunologic therapies that reduce platelet survival (distinct from “production,” but commercially adjacent)

If the goal is to decrease platelet production (megakaryopoiesis) rather than platelet survival, the highest-fit mechanism is JAK pathway modulation in MPNs, where platelet production is a disease driver.

What is the Orange Book status of leading platelet-lowering therapies?

Orange Book coverage is only directly meaningful for FDA-approved small molecules and biologics with listed patents. For MPN therapies that are branded and FDA-approved, Orange Book listings typically include:

• active ingredient/process patents
• formulation and dosage form patents
• method-of-use patents tied to indications such as essential thrombocythemia or other platelet-related indications (where applicable)

Market implication

• Orange Book-listed patents determine Hatching eligibility and Paragraph IV strategy for ANDA filers for small molecules.
• For biologics, the parallel system is BLA/biologics exclusivity and patent listings in the “Purple Book” framework.

When do drugs that decrease platelet counts lose exclusivity?

Exclusivity is driven by the first approval date and regulatory exclusivity categories, while patent expiration is determined by the earliest non-provisional priority and terminal disclaimers. For platelet-lowering therapies, two timelines matter for generic or biosimilar risk:

1. regulatory exclusivity (data exclusivity, new chemical entity (NCE), new therapeutic biological product (NSEP), pediatric exclusivity, orphan if granted)
2. patent expiration (utility patents, method-of-use patents, formulation patents)

How do exclusivity and patent expiration timelines affect generic launch risk?

Rule-of-thumb for risk mapping

• If the active ingredient is a first-in-class JAK inhibitor or has multiple indication-specific method patents, generic/ANDA risk can remain low until the last blocking patent expires or is successfully challenged via Paragraph IV.
• If the product has broad formulation or process patents that are hard to design around, litigation often centers on those barriers.

Decision-useful timeline structure

• Earliest priority date → earliest utility expiration (plus prosecution history effects)
• NDA first approval → NCE/data exclusivity window
• Orphan drug exclusivity (if granted) → 7-year brand exclusivity from approval
• Pediatric exclusivity (if applicable) → 6-month extension

Market implication

• The most aggressive generic challenges usually target the smallest number of blocking patents that determine “eligibility” to launch upon expiration.

Which patents protect method of use for lowering platelet counts?

Method-of-use patents are common where the clinical positioning ties platelet response to a defined patient population. Patent coverage typically includes:

• treatment of essential thrombocythemia or related MPNs with thrombocytosis
• dosing regimens that achieve platelet count thresholds
• management of platelet count over time

What do method-of-use patents typically claim?

Common claim elements in platelet-lowering MPN method patents include:

• patient selection criteria (diagnosis, biomarker status, or risk stratification)
• dose ranges and titration schedules
• target platelet count ranges or time-to-response endpoints
• combination regimens with other cytoreductive or antiplatelet therapies

Design-around difficulty

• Harder to enter via ANDA if the method-of-use patents are tied to a unique dosing or monitoring protocol that is not just “use of compound X,” but a regimen with defined steps and thresholds.

How many patents cover formulations that reduce platelet production, and can generics design around them?

For small molecules, formulation patents often cover:

• immediate vs extended release profiles
• specific solid-state forms (polymorphs, amorphous forms)
• particle size and milling parameters
• stability and dissolution profiles
• manufacturing processes for the drug substance or drug product

What formulation patents drive litigation frequency?

Formulation patents become litigation focal points when:

• the generic’s bioequivalence can be met with different formulation
• but the listed patent claims a specific solid state or stability-enhanced form
• or when the reference product uses a proprietary manufacturing process that is indirectly captured by product-by-process claims

Market implication

• Even if active ingredient patents expire, formulation patent lifetimes can delay launch.

What patent litigation affects platelet-lowering drugs?

Platelet-lowering products show predictable litigation patterns:

• Paragraph IV filings on ANDA attempts around the active ingredient and method-of-use claims
• settlement-driven “carve-out” dates that function like de facto exclusivity extensions

Typical litigation and settlement structures for ANDA launches

Common outcomes:

• dismissal without prejudice for claim construction disputes
• 30-month stay expiration with court rulings that narrow or eliminate infringement theories
• settlement agreements that set a stated launch date even when patents expire later or are contested

Commercial impact

• Settlements frequently create a delayed entry date that investors and pipeline teams treat as the real launch deadline.

What generic entry risks exist for drugs that decrease platelet production?

Generic entry risk is primarily determined by:

• number of unexpired Orange Book patents at the time of the first generic filing
• strength of infringement posture for those patents
• likelihood of district court claim construction limiting generic reach

How does the number of blocking patents change the ANDA playbook?

High-blocker estates tend to:

• reduce the number of Paragraph IV challengers
• increase willingness to file later in the patent term
• concentrate litigation among the few filers that can finance long, multi-patent disputes

Market implication

• If a platelet-lowering therapy has multiple formulation and method-of-use patents, the “first wave” generic launches are less common.

What is the biosimilar risk for platelet-lowering therapies?

“Decreased platelet production” as an effect can be achieved by biologics that affect platelet survival, immune pathways, or cytokine signaling. Biosimilar risk depends on whether the product is biologic and:

• whether the mechanism is indirect or requires specific glycoforms (for monoclonals or cytokine analogs)
• whether patents include biosimilar-relevant claims around epitopes, sequences, or methods

Are biologics common in platelet-lowering indications?

Biologics exist in platelet management (especially immune-mediated thrombocytopenia contexts), but the densest “platelet production” patent ecosystems in mainstream MPN platelet lowering tend to be small molecules rather than biologics.

How does each mechanism class affect market dynamics for platelet-lowering drugs?

Platelet-lowering demand is shaped by diagnosis mix and clinical monitoring burden.

Category 1: MPN platelet-lowering small molecules (JAK pathway modulation)

• Market drivers: thrombocytosis prevalence, risk stratification needs, resistance/intolerance to older cytoreductives, line-of-therapy behavior.
• Switching friction: clinicians consider safety tolerability, lab monitoring, and disease control endpoints.
• Patent dynamics: method-of-use and dosing patents are often used to prevent launch until regimen equivalence is established.

Category 2: Cytotoxic or broadly immunosuppressive agents (thrombocytopenia as a consequence)

• Market drivers: oncology or autoimmune indications, with platelet count reduction not the primary endpoint.
• Patent dynamics: fewer “platelet production” indication-specific patents; generics face fewer direct barriers tied to the platelet effect.

Category 3: Immune-mediated thrombocytopenia biologics or antibodies (platelet survival)

• Market drivers: chronic immune thrombocytopenia response needs, prior therapy failures, durability.
• Patent dynamics: epitope, sequence, formulation stability, and method-of-use claims drive biosimilar and generic strategy.

Key comparison: how patent estates differ across platelet-lowering mechanisms

Mechanism class	Primary regulatory positioning	Likely patent focus	Generic/biosimilar risk driver	Typical litigation posture
JAK/TPO-pathway small molecules for MPN thrombocytosis	Indication-specific platelet lowering	method-of-use, dosing, formulation/solid state, manufacturing	blocking Orange Book patents + claim construction	multi-patent Paragraph IV disputes and settlements
Cytotoxic agents causing thrombocytopenia	Not primarily platelet production	older composition/process; less direct method-of-use	earlier expiration and fewer indication-specific barriers	lower incidence of platelet-effect-focused patent wars
Immune therapies affecting platelet survival	Indirect to “production,” but platelet count lowering	biologic sequence/epitope, formulation, use claims	biosimilarity and IP around biologics-relevant properties	biosimilar-specific litigation and regulatory design-around

What do FDA regulatory milestones look like for platelet-lowering products?

For exclusivity and entry, the key FDA milestones include:

• NDA/BLA submission and first approval date
• label expansions that can trigger additional method-of-use or formulation filings
• post-approval safety or label narrowing that can impact enforceable scope in litigation

Regulatory impact on IP

• New indications can add method-of-use patents that extend practical exclusivity even when the core active ingredient expires.

Where do the strongest commercial barriers usually sit: patents or clinical practice?

For platelet count lowering, the practical barriers are:

• lab monitoring protocols and dosing titration requirements
• patient selection criteria and clinician trust in response curves
• tolerability management that is tied to regimen details that patents often cover

Market implication

• Even after patent expiry of core composition claims, method/regimen patents can prevent or delay full therapeutic substitutability.

---

Key Takeaways

• The most direct IP-dense “decreased platelet production” category is MPN-focused platelet-lowering using pathway modulation, where method-of-use and dosing patents are common and can delay ANDA entry.
• Exclusivity timelines (NCE/data, orphan if applicable, pediatric extension) set the earliest regulatory entry window; patent estates determine whether Paragraph IV challenges can succeed.
• Formulation and solid-state patents are frequent litigation targets because they can preserve exclusivity even when composition patents end.
• Generic launch risk is highest when only a small set of Orange Book patents block entry; it is lowest when multiple method-of-use and formulation patents remain unexpired.
• Biosimilar risk depends on whether platelet-lowering is achieved through biologics; where biologics are involved, epitope/sequence and biologics-relevant formulation patents drive the strategy.

---

FAQs

1) What is the typical claim structure of method-of-use patents for platelet-lowering in MPNs?
Patient selection plus dosing/titration steps, target platelet ranges, and time-to-response endpoints.

2) What Orange Book patent types most often block ANDA launches for platelet-lowering small molecules?
Method-of-use and formulation/solid-state patents linked to labeled regimens and product performance.

3) How do settlement agreements change real-world launch timing for platelet-lowering generics?
They create de facto entry dates via agreed launch conditions even while patent scope remains litigated.

4) Which factors accelerate or delay clinical switching after platelet-lowering therapy patent expiry?
Dosing titration familiarity, tolerability management, and lab-monitoring workflow alignment.

5) How does a label expansion for a platelet-lowering indication affect patent strategy?
It can trigger additional method-of-use filings that extend practical blocking patent coverage for ANDA/biosimilar attempts.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA. Drugs@FDA. US Food and Drug Administration.
3. FDA. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. US Food and Drug Administration.
4. FDA. Hatch-Waxman and Patent Certifications. US Food and Drug Administration.
5. FDA. Guidance for Industry: Considerations for Biosimilar Development. US Food and Drug Administration.